Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atreleuton

Next Previous
X
Search
Drug Profile

Atreleuton

Alternative Names: A 85761; ABT 761; VIA 2291

Latest Information Update: 08 Feb 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer VIA Pharmaceuticals
  • Class Anti-inflammatories; Cardiovascular therapies; Small molecules; Urea compounds
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Asthma; Atherosclerosis

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 20 May 2010 Updated pharmacodynamics data from a substudy of a Phase-II trial in Acute coronary syndromes released by VIA Pharmaceuticals
  • 14 May 2009 VIA Pharmaceuticals completes enrolment in its second phase II trial for Acute coronary syndromes in the USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top